Skip to main content

Table 1 Clinical, Cytogenetics and Pathological Data

From: Assessing karyotype precision by microarray-based comparative genomic hybridization in the myelodysplastic/myeloproliferative syndromes

Number of patients 30
Gender (M/F) 18/12
Age at study, range (median) 19-87 (64 yr)
Peripheral blood values (n = 29)  
   WBC* (K/CMM) range (median) 1.2 - 45.5 (3.1)
   Hb* (g/dl) range (median) 7.4-15.6 (9.8)
   Platelet* (K/CMM) range (median) 14 - 598 (82)
   Eosinophils* % range (median) 0-9.2 (1.3)
Bone marrow blasts, range (median) 0-31% (8.0%)
Cellularity  
   Hypercellular 17
   Normocellular 7
   Hypocellular 4
   Fibrotic or aparticulate 2
FAB#  
   RA 1
   RARS 2
   RAEB 15
   RAEB-t 5
   Refractory cytopenia, NOS 2
   Hypoplastic MDS 1
   MDS, NOS 1*
   MPN → AML 1
   Idiopathic myelofibrosis 1
   Abnormal cytogenetics 1
WHO  
   5q-syndrome 1
   RARS 1
   RCMD 2
   RAEB-1 2
   RAEB-2 8
   AML 3
   t-MDS 8
   t-AML 2**
Other pathology  
   AA/hypoplastic MDS 1
   Primary myelofibrosis 1
   Cytogenetic abn only^ 1
IPSS score - for 16 patients  
   HIGH 2
   INT-2 10
   INT-1 2
   LOW 2
History of previous chemo- or radiotherapy 14^
  1. # Samples were submitted with a working diagnosis of MDS. Pathology review revealed the myeloid diagnoses presented in this table. *Aspirate was aparticulate and hemodilute (insufficient for pathology review). **Blast percentage between 22-31% when sample underwent morphologic evaluation. ^Patients were previously treated for AML (4), MDS (1), Hodgkin lymphoma (3), non-lymphoma (3), breast cancer (1), prostate (1), and prostate/kidney cancer (1).